scout
Commentary|Videos|December 15, 2023

Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Ajai Chari, MD, director, Multiple Myeloma Program, professor of clinical medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab-tgvs (Talvey) in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study (NCT03399799/NCT04634552).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME